Literature DB >> 17362681

The endovascular management of intracranial vascular disease including the MERCI device.

Chirag D Gandhi1, David M Johnson, Aman B Patel.   

Abstract

The prompt and aggressive management of acute stroke has become the standard of care as public awareness and the available successful treatment options both increase. The intravenous administration of tissue plasminogen activator within an established treatment window has been determined through large well-designed studies. The endovascular strategies for acute stroke have evolved significantly over the past 5 years and have been prompted by the limits of the intravenous treatment, as well as by the desire to demonstrate improved recanalization rates and improved long-term outcomes. Among these interventional treatment options are the intra-arterial administration of tissue plasminogen activator and newer antiplatelet agents, mechanical thrombectomy with the MERCI device, and intracranial angioplasty and stenting. This article outlines the major studies that have defined the current field of acute stroke management and discusses the basic treatment paradigms that are commonly utilized today.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17362681     DOI: 10.1007/s11886-007-0006-9

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  37 in total

1.  Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

Authors:  A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

2.  Devices, drugs, and the Food and Drug Administration: increasing implications for ischemic stroke.

Authors:  Anthony J Furlan; Marc Fisher
Journal:  Stroke       Date:  2005-01-06       Impact factor: 7.914

3.  Approval of the MERCI clot retriever: a critical view.

Authors:  Kyra J Becker; Thomas G Brott
Journal:  Stroke       Date:  2005-01-13       Impact factor: 7.914

4.  Hemorrhage in the Interventional Management of Stroke study.

Authors: 
Journal:  Stroke       Date:  2006-01-26       Impact factor: 7.914

Review 5.  Thrombolytic therapy for ischemic stroke--a review. Part I--Intravenous thrombolysis.

Authors:  P D Schellinger; J B Fiebach; A Mohr; P A Ringleb; O Jansen; W Hacke
Journal:  Crit Care Med       Date:  2001-09       Impact factor: 7.598

6.  Rescue localized intra-arterial thrombolysis for hyperacute MCA ischemic stroke patients after early non-responsive intravenous tissue plasminogen activator therapy.

Authors:  Dong Joon Kim; Dong Ik Kim; Seo Hyun Kim; Kyung Yeol Lee; Ji Hoe Heo; Sang Won Han
Journal:  Neuroradiology       Date:  2005-06-28       Impact factor: 2.804

7.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

8.  Middle cerebral artery occlusion: correlation of computed tomography and angiography with clinical outcome.

Authors:  I Saito; H Segawa; Y Shiokawa; M Taniguchi; K Tsutsumi
Journal:  Stroke       Date:  1987 Sep-Oct       Impact factor: 7.914

9.  Does arterial recanalization improve outcome in carotid territory stroke?

Authors:  R von Kummer; R Holle; L Rosin; M Forsting; W Hacke
Journal:  Stroke       Date:  1995-04       Impact factor: 7.914

10.  Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study.

Authors:  R L Sacco; D E Kargman; Q Gu; M C Zamanillo
Journal:  Stroke       Date:  1995-01       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.